Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Autoantibody Response Toward Chromatin in Patients With Juvenile Idiopathic Arthritis

Pitkänen, Viola; Remes-Pakarinen, Terhi; Vähäsalo, Paula; Möttönen, Milja; Grönlund, Minna-Maija; Arvonen, Miika; Knip, Mikael; Veijola, Riitta; Toppari, Jorma; Ilonen, Jorma; Lempainen, Johanna; Schroderus, Anna-Mari; Kröger, Liisa; Kinnunen, Tuure

Autoantibody Response Toward Chromatin in Patients With Juvenile Idiopathic Arthritis

Pitkänen, Viola
Remes-Pakarinen, Terhi
Vähäsalo, Paula
Möttönen, Milja
Grönlund, Minna-Maija
Arvonen, Miika
Knip, Mikael
Veijola, Riitta
Toppari, Jorma
Ilonen, Jorma
Lempainen, Johanna
Schroderus, Anna-Mari
Kröger, Liisa
Kinnunen, Tuure
Katso/Avaa
Arthritis Rheumatology - 2025 - Pitkänen - Autoantibody Response Toward Chromatin in Patients With Juvenile Idiopathic.pdf (6.774Mb)
Lataukset: 

John Wiley & Sons
doi:10.1002/art.43315
URI
https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.43315
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe202601215874
Tiivistelmä

Objective. Patients with juvenile idiopathic arthritis (JIA) frequently exhibit antinuclear antibodies (ANAs), but the specific antigen target recognized by them and the presence of additional autoantibody specificities in patients with JIA remains elusive.

Methods. Plasma samples from 110 untreated patients with active JIA, as well as from 14 children with unspecified arthritis and 151 age- and sex-matched healthy children, were analyzed with multiple modern clinical-grade autoantibody assays, including automated indirect immunofluorescence to screen for ANAs with HEp-2 cells, and specific immune assays to detect reactivity to individual autoantigens. In addition, a HuProt proteome microarray was used to screen for novel autoantibody targets in plasma samples from five patients with ANA-positive JIA and four ANA-negative healthy controls.

Results. Homogeneous nuclear ANA staining, indicating reactivity toward chromatin, was detected in most (61.8%) patients with JIA but rarely in healthy controls (2.6%; P < 0.0001). No antibody reactivity to specific nuclear antigens or other autoantigens associated with connective tissue diseases was detected. However, 20% of patients with JIA harbored antibodies against double-stranded DNA (dsDNA)-nucleosome complexes (compared with 2.6% of controls, P < 0.0001). Finally, the proteome microarray revealed core histone H2A variant H2AFY, part of the nucleosome, to be the most widely recognized human protein by autoantibodies of patients with JIA.

Conclusion. Autoantibody reactivity in JIA primarily targets chromatin, but the epitopes targeted are likely either posttranslationally modified or multimolecule epitopes, such as dsDNA-nucleosome complexes, rather than epitopes on individual native proteins or purified dsDNA.

Kokoelmat
  • Rinnakkaistallenteet [29337]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste